Table 2.
No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model/In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
---|---|---|---|---|---|
1 | Gelatin–Dextran | Self-assembly-Genipin-Crosslinking | Plant polyphenols | Breast cancer MCF-7 | [26] |
2 | Gelatin–Dextran | Self-assembly-Genipin-Crosslinking | Curcumin | Cervical cancer HeLa Healthy mice | [27] |
3 | Casein | Self-assembly | Curcumin | Cervical cancer HeLa | [32] |
4 | Zein–PEG | Self-assembly | Curcumin | Ovarian cancer NCI Healthy mice | [33] |
5 | Chitosan–Stearic acid | Self-assembly | Curcumin | Colon cancer Primary Xenograft mice | [34] |
6 | PEG–Polyanhydride esters | Solvent evaporation | Curcumin | Cervical cancer HeLa | [35] |
7 | PEG–Polylactic acid | Solvent evaporation | Curcumin + Doxorubicin | Breast cancer MCF-7 Xenograft mice | [36] |
8 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Ovarian cancer A2780t | [38] |
9 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Breast cancer MDA-MB-436 | [37] |
10 | PEG–Polycaprolactone | Self-assembly | Curcumin | Breast cancer 4T1–4T1 Xenograft mice | [40] |
11 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Cervical cancer HeLa Xenograft mice | [39] |
12 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Colon HT-29 | [39] |
13 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin + Doxorubicin | Lung cancer LL/2 Xenograft mice | [41] |
14 | Linoleic acid-PEG-Polycaprolactone | Self-assembly | Curcumin | Cervical cancer HeLa Healthy mice | [43] |
15 | Linoleic acid-PEG-Polycaprolactone | Self-assembly | Curcumin | Lung A549 | [43] |
16 | PEG -Palmitic acid | Self-assembly | Curcumin | Cervical cancer HeLa | [32] |
17 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Paclitaxel | Ovarian cancer SK-OV-3TR | [45] |
18 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Paclitaxel | Ovarian cancer NCI SK-OV-3TR Xenograft mice | [46] |
19 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Doxorubicin | Colon cancer HCT-116 Xenograft mice | [44] |
20 | PEG- Doxorubicin | Self-assembly | Curcumin + Doxorubicin | Cervical cancer HeLa HepG2 Xenograft mice | [47] |
21 | PEG-Doxorubicin | Self-assembly | Curcumin + Doxorubicin | Hepatic HepG2 | [47] |
22 | Poloxamers F127 F68 | Thin-layer evaporation | Curcumin | Cervical cancer HeLa | [48] |
23 | Poloxamers-PEG-Succinate | Solvent evaporation | Curcumin | Ovarian cancer NCI | [49] |
24 | Poloxamers F127 | Thin-layer evaporation | Resveratrol, Curcumin + Doxorubicin | Ovarian cancer SKOV-3 Healthy mice | [50] |
25 | Poloxamers F127 | Thin-layer evaporation | Resveratrol, Quercetin + Doxorubicin | Ovarian cancer SKOV-3 Healthy mice | [31] |
26 | Apolipoprotein-E3 | recombinant DNA | Resveratrol | Glioblastoma A-172 | [51] |
27 | Polycaprolactone-PEG-Succinate | Thin-layer evaporation | Resveratrol | Breast cancer MCF-7 | [52] |
28 | Casein | Self-assembly | Epigallocatechin gallate | Colon cancer HT-29 | [53] |
29 | Polylactic acid-PEG | Thin-layer evaporation | Epigallocatechin gallate | Pancreatic cancer MiaPaca-2 | [54] |
Note: PEG2000-DSPE—1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxypolyethylene glycol-2000].